Brown Advisory Inc. boosted its position in Teleflex Incorporated (NYSE:TFX) by 725.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,089 shares of the medical technology company’s stock after purchasing an additional 21,170 shares during the period. Brown Advisory Inc. owned approximately 0.05% of Teleflex worth $6,226,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FMR LLC lifted its position in shares of Teleflex by 632.5% during the 3rd quarter. FMR LLC now owns 1,343,305 shares of the medical technology company’s stock valued at $357,440,000 after acquiring an additional 1,159,914 shares during the last quarter. Atlanta Capital Management Co. L L C lifted its position in shares of Teleflex by 17.7% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 2,650,228 shares of the medical technology company’s stock valued at $705,199,000 after acquiring an additional 399,301 shares during the last quarter. William Blair Investment Management LLC lifted its position in shares of Teleflex by 52.1% during the 3rd quarter. William Blair Investment Management LLC now owns 955,428 shares of the medical technology company’s stock valued at $254,230,000 after acquiring an additional 327,451 shares during the last quarter. Villere ST Denis J & Co. LLC acquired a new stake in shares of Teleflex during the 4th quarter valued at $59,564,000. Finally, BlackRock Inc. lifted its position in shares of Teleflex by 2.8% during the 3rd quarter. BlackRock Inc. now owns 4,993,747 shares of the medical technology company’s stock valued at $1,328,788,000 after acquiring an additional 135,484 shares during the last quarter. Hedge funds and other institutional investors own 91.17% of the company’s stock.
In other news, VP John Deren sold 125 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $290.43, for a total value of $36,303.75. Following the completion of the sale, the vice president now owns 2,539 shares in the company, valued at $737,401.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas E. Powell sold 5,324 shares of the stock in a transaction on Thursday, December 27th. The shares were sold at an average price of $242.25, for a total value of $1,289,739.00. Following the completion of the sale, the chief financial officer now owns 13,775 shares of the company’s stock, valued at approximately $3,336,993.75. The disclosure for this sale can be found here. Insiders sold 21,924 shares of company stock valued at $5,828,431 in the last 90 days. Corporate insiders own 2.56% of the company’s stock.
TFX opened at $302.90 on Friday. The firm has a market capitalization of $13.81 billion, a PE ratio of 30.60, a price-to-earnings-growth ratio of 1.99 and a beta of 1.06. Teleflex Incorporated has a 12-month low of $226.02 and a 12-month high of $302.95. The company has a quick ratio of 1.39, a current ratio of 2.12 and a debt-to-equity ratio of 0.82.
Teleflex (NYSE:TFX) last released its earnings results on Thursday, February 21st. The medical technology company reported $2.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.76 by $0.01. The company had revenue of $641.60 million during the quarter, compared to analyst estimates of $641.06 million. Teleflex had a return on equity of 18.47% and a net margin of 8.20%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.44 earnings per share. Sell-side analysts anticipate that Teleflex Incorporated will post 11.02 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were issued a $0.34 dividend. The ex-dividend date was Thursday, February 28th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.45%. Teleflex’s payout ratio is currently 13.74%.
A number of equities research analysts have recently commented on the company. Zacks Investment Research upgraded Teleflex from a “sell” rating to a “hold” rating in a research report on Tuesday, February 26th. Morgan Stanley increased their price objective on Teleflex from $305.00 to $315.00 and gave the company an “overweight” rating in a research report on Tuesday, February 26th. Barclays set a $287.00 price objective on Teleflex and gave the company a “hold” rating in a research report on Friday, February 22nd. Needham & Company LLC reiterated a “strong-buy” rating and set a $325.00 price objective (up previously from $300.00) on shares of Teleflex in a research report on Friday, February 22nd. Finally, TheStreet upgraded Teleflex from a “c+” rating to a “b-” rating in a research report on Wednesday, November 28th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $297.00.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2019/03/17/teleflex-incorporated-tfx-shares-bought-by-brown-advisory-inc.html.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Story: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.